Yhn HealthMental Health first seen 5 d ago, last 47 min ago, peak #1
One-Shot CRISPR Therapies Targeting PCSK9 for Cholesterol
Original: In-Vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
A new review examines in-vivo CRISPR and base-editing therapies that target the PCSK9 gene with a single treatment, an approach aimed at permanently lowering LDL cholesterol and reducing heart disease risk. Unlike statins, which require daily medication, these one-time gene-editing infusions could offer lasting cholesterol control. Early clinical results from companies in this space have drawn attention, and the review outlines progress, safety questions, and what remains before such therapies become routine care.
Why now: Recent progress toward single-dose gene-editing treatments for high cholesterol suggests a potential alternative to lifelong statin therapy.
PCSK9CRISPRVerve TherapeuticsSpringer
Rank over time, top of the chart is #1. 9 snapshots from 11 h ago to 47 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3255814